March 24, 2020 / 12:38 PM / 12 days ago

BRIEF-Oncolytics Biotech® Announces Favourable Aware-1 Safety Update

March 24 (Reuters) - Oncolytics Biotech Inc:

* ONCOLYTICS BIOTECH® ANNOUNCES FAVOURABLE AWARE-1 SAFETY UPDATE

* ONCOLYTICS BIOTECH - COHORT 1 SHOWED WIDESPREAD VIRAL REPLICATION IN MAJORITY TUMORS WITH CREATION OF PRO-INFLAMMATORY EFFECT IN TUMOR MICROENVIRONMENT

* ONCOLYTICS BIOTECH INC - NO NEGATIVE EFFECTS TO HEALTHY TISSUE WERE NOTED IN STUDY

* ONCOLYTICS BIOTECH - SAFETY COMMITTEE APPROVED AMENDMENT OF STUDY TO LOWER DOSE OF TECENTRIQ TO BE CURRENTLY APPROVED BREAST CANCER DOSE OF 840MG

* ONCOLYTICS BIOTECH INC - STUDY WILL CONTINUE TO ENROLL PATIENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below